Xcout Intel
Vogenx, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Vogenx, Inc. among biotech companies — ranked by similarity to what Vogenx, Inc. actually does, not by market-cap band.
Subscribe to see Vogenx, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Vogenx, Inc.
Vogenx, Inc. is a clinical-stage biopharmaceutical and life science company that discovers and develops novel therapeutics to treat metabolic and gastrointestinal diseases, including post-bariatric hypoglycemia and gastroparesis. Its lead drug candidate, mizagliflozin, is an oral small molecule designed to inhibit SGLT1, reducing glucose absorption and the secretion of insulin and gastric inhibitory peptide.
Vogenx, Inc. at a glance
Vogenx, Inc. is a biotech company headquartered in Raleigh, United States. Xcout tracks 11 named people at Vogenx, Inc., including James Green (President, CEO & Chairman).
Vogenx, Inc. leadership
- James GreenPresident, CEO & Chairman
- Steven R. DelmarCFO, Corporate Secretary & Director
- Steven DelmarChief Financial Officer
- William WilkisonChief Scientific Officer, Chair of Scientific Advisory Board & Director
- James GreenExecutive Officer
- Steven DelmarExecutive Officer
5 more named people on record for Vogenx, Inc., with roles, board committees and tenure — see the full roster →
Vogenx, Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $11M | — |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Vogenx, Inc. news
- IPOVogenx (proposed Nasdaq: VOGX) IPO aims to lift cash to ...
- IPOVogenx Inc Common Stock IPO on NASDAQ
- IPOIPO registration (S-1)
- IPOA small drug company based in Raleigh is targeting the public ...
6 corporate events on record, with sources — see the full timeline →
Top 12 Vogenx, Inc. competitors
Ranked by semantic similarity — how close each company is to Vogenx, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Biotechnology
Aclipse Therapeutics is a clinical-stage biopharmaceutical company that develops novel, disease-modifying drug candidates for severe and life-threatening conditions such as gastroparesis and amyotrophic lateral sclerosis (ALS). The company leverages genomic, proteomic, and biomarker data to target molecular pathways involving inflammation, cellular stress, and protein misfolding, while also implementing patient stratification approaches to improve clinical outcomes.
Biotechnology
Syntis Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to revolutionizing oral therapies for obesity and metabolic diseases.
Biotechnology
DiogenX is a preclinical-stage biotechnology company headquartered in Marseille, France, with research laboratories in Nice, dedicated to developing novel treatments for diabetes.
Similar biotech company
Guangzhou Innogen Pharmaceutical Group Co Ltd operates as a China-based investment holding firm with a core mission to research, develop, and bring to market medicinal products. The company specializes in producing innovative, human-compatible, and extended-duration GLP-1 receptor agonists, specifically targeting the treatment of diabetes and other metabolic conditions.
Biotechnology
D&D Pharmatech Inc. is a clinical-stage biotechnology company specializing in the development of GLP-1 receptor agonists and proprietary peptide technologies.
Biotechnology
Metabolic Solutions Development Company is a private biotechnology and drug discovery company founded in 2006. The firm focuses on investigating novel molecular targets and developing therapeutics to treat diabetes, metabolic syndrome, and related conditions.
Biotechnology
Regenacy Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts. The company focuses on developing breakthrough treatments for diabetic neuropathies and other debilitating conditions.
Biotechnology
Adocia is a clinical-stage biotechnology company that develops innovative formulations of proteins, peptides, and metabolic hormones. The company specializes in creating treatments for diabetes and obesity, as well as immunoprotective scaffolds for cell therapies.
Biotechnology
VectivBio was a Swiss clinical-stage biopharmaceutical company focused on developing therapies for severe gastrointestinal and rare diseases. Its lead asset, apraglutide, was being developed for short bowel syndrome with intestinal failure and other conditions involving intestinal dysfunction, serving patients with serious gastrointestinal disorders.
Biotechnology
Atrogi is a clinical-stage biotechnology company headquartered in Stockholm, Sweden, pioneering the development of novel treatments for metabolic disorders.
Biotechnology
Inversago Pharma is a Canadian biotechnology company developing peripherally restricted CB1 receptor antagonists/inverse agonists for metabolic, fibrotic, and related diseases. Its drug-development programs are intended to serve patients with conditions such as obesity, metabolic syndrome, and diabetic kidney disease.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Vogenx, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Vogenx, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →